2025.11.11
TCROSS Co., Ltd. announced that it will introduce its new service, InsighTCROSS EarlyScripters, at MEDICA 2025, the world’s largest medical technology exhibition, to be held in Düsseldorf, Germany, from November 17 to 20, 2025.
The newly launched EarlyScripters model enables companies to identify physicians who are most likely to prescribe a new drug at the earliest stage—so-called “early adopters.” It also allows nationwide exploration of physicians with similar characteristics and predicts their prescribing probability.
Early adoption of new drugs is said to account for approximately 80% of early product success1）, making it a crucial factor in launch performance. However, only about 30% of new drugs achieve their first-year forecast2）. EarlyScripters was developed to improve this probability and support faster return on early investments.
With InsighTCROSS and EarlyScripters, TCROSS aims to move beyond traditional sales approaches based on intuition and experience, offering a more data-driven and quantitative approach to commercial decision-making in the pharmaceutical and medical device industries.
InsighTCROSS is a decision-support model developed by TCROSS Co., Ltd. for pharmaceutical and medical device companies. By integrating statistical analysis and data science with traditional sales and marketing practices, InsighTCROSS enables the visualisation of physicians’ prescribing behaviours and decision-making criteria. This approach supports more effective strategy development, allowing companies to optimise resource allocation and reduce marketing costs. Ultimately, InsighTCROSS contributes to more appropriate healthcare spending and the advancement of a sustainable healthcare system.